Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands

BACKGROUND: To explore the effectiveness and safety of the gonadotropin-releasing hormone antagonist, Degarelix, for the treatment of advanced hormone-dependent prostate cancer (PCa) in a real-world setting. METHODS: In this noninterventional study, patients with advanced hormone-dependent PCa were...

Descripción completa

Detalles Bibliográficos
Autores principales: Roshani, Hossain, Roos, Erik P.M., Elzevier, Henk W., van de Beek, Cees, van Winkel, Peter, Pelger, Rob C.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772641/
https://www.ncbi.nlm.nih.gov/pubmed/35069083
http://dx.doi.org/10.1097/CU9.0000000000000029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772641/
https://www.ncbi.nlm.nih.gov/pubmed/35069083
http://dx.doi.org/10.1097/CU9.0000000000000029

Ejemplares similares